Cogent Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Cogent Biosciences, Inc. on June 9, 2026. The record date for the meeting was April 13, 2026, with 170,801,004 shares of common stock entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
All proposals submitted to the stockholders were approved, and all director nominees were elected. The specific voting results are as follows:
- Proposal 1: Election of Directors
- Chris Cain, Ph.D.: 124,356,809 For; 18,837,092 Withheld; 11,240,612 Broker Non-Votes.
- Arlene Morris: 120,180,517 For; 23,013,384 Withheld; 11,240,612 Broker Non-Votes.
- Todd Shegog: 124,143,441 For; 19,050,460 Withheld; 11,240,612 Broker Non-Votes.
- Proposal 2: Ratification of PricewaterhouseCoopers LLP
- 154,001,553 For; 399,367 Against; 33,593 Abstentions; 0 Broker Non-Votes.
- Proposal 3: Advisory Vote on Executive Compensation
- 129,183,846 For; 13,977,449 Against; 32,606 Abstentions; 11,240,612 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investors to Verify
- Confirmation that all three director nominees (Cain, Morris, Shegog) were successfully re-elected.
- Verification of the significant number of broker non-votes (11,240,612) on director elections and executive compensation.
- Confirmation of the ratification of PricewaterhouseCoopers LLP as the independent auditor.